United KingdomA recent phase III clinical trial showed that patients with melanoma who received a personalized cancer vaccine called intismeran lived longer without cancer recurrence compared to those who did not receive the vaccine. The trial involved over 1,100 participants and was conducted by pharmaceutical companies Merck and Moderna. This follows a successful phase II trial in 2024 with 157 participants. If approved, intismeran would be the first cancer vaccine for melanoma and the second therapeutic cancer vaccine overall, following sipuleucel-T for prostate cancer. Personalized cancer vaccines target specific tumor mutations and could potentially be applicable to various types of cancer. Ongoing trials are exploring their use in melanoma, lung cancer, bladder cancer, and kidney cancer.
Bias read (Center): The article discusses scientific advancements in personalized cancer vaccines without taking a stance on political issues. It focuses on medical research and clinical trials, presenting findings objectively without apparent bias toward any political ideology or group.
